COLGATE U.S. TOOTHPASTE MANUFACTURING TO BE CONSOLIDATED IN INDIANA as the company moves to unify its manufacturing facilities for product categories into "focused factories," Colgate-Palmolive announced Sept. 20. The firm is reassigning its Jeffersonville, Ind. plant's liquid dishwashing detergent manufacturing responsibilities to one of Colgate's "focused liquids facilities," and contracting out the plant's powder detergent jobs to a "state-of-the-art" manufacturer, Colgate explained. These moves will make the Jeffersonville plant the "U.S. focused factory primarily for toothpaste."
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.
India is pressing ahead with “big shifts” in its regulatory approach for cell and gene therapies. Reduced “layers of review”, tighter internal timelines, upcoming guidelines to facilitate CGT development and reforms in the constitution of expert committees are some of the key changes.
US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.
India is pressing ahead with “big shifts” in its regulatory approach for cell and gene therapies. Reduced “layers of review”, tighter internal timelines, upcoming guidelines to facilitate CGT development and reforms in the constitution of expert committees are some of the key changes.
After almost seven years, China’s NMPA has once again published draft measures for clinical trial data protection, opening these up to public comments. While specific protection periods by drug category are proposed, some clarifications are still needed.
